Tags
- A
- Accelerated approval
- Behind
- Boulder, Colorado
- BRCA mutation
- Breast
- Breast cancer
- Bristol Myer
- Cancer
- Cancer Research Institute
- Chapter 11, Title 11, United States Code
- Chemotherapy
- Clovis culture
- Colorado
- Daiichi Sankyo
- DOI
- Durata Therapeutics
- Exelixis
- Fibroblast growth factor receptor 1
- Fibroblast growth factor receptor 2
- Food and Drug Administration
- Fox Business Network
- Germline mutation
- Incyte
- International Standard Serial Number
- Lancet
- Left
- Left Behind
- MedImmune
- Medpace
- NASDAQ
- NASDAQ Biotechnology Index
- New
- Non-small-cell lung carcinoma
- Oncology
- Osimertinib
- Ovarian cancer
- PARP inhibitor
- People
- Pharmaceutical industry
- Preclinical imaging
- Proton therapy
- Public company
- PubMed
- Rucaparib
- Russell 2000 Index
- Somatic evolution in cancer
- The Lancet
- Ticker symbol
- U.S. Securities and Exchange Commission
- VEGF receptor